Ikena Oncology (NASDAQ:IKNA – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a research report issued to clients and investors on Thursday, RTT News reports.
A number of other equities research analysts have also issued reports on the stock. HC Wainwright decreased their price objective on shares of Ikena Oncology from $18.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. Wedbush assumed coverage on Ikena Oncology in a report on Thursday, September 21st. They set an “outperform” rating and a $11.00 price target on the stock.
Ikena Oncology Stock Up 6.4 %
Institutional Investors Weigh In On Ikena Oncology
Several institutional investors and hedge funds have recently modified their holdings of IKNA. JPMorgan Chase & Co. increased its position in shares of Ikena Oncology by 25.4% during the first quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock valued at $104,000 after buying an additional 3,482 shares during the period. BlackRock Inc. raised its position in shares of Ikena Oncology by 9.5% in the 1st quarter. BlackRock Inc. now owns 1,493,161 shares of the company’s stock worth $9,108,000 after acquiring an additional 129,284 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Ikena Oncology by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 789,999 shares of the company’s stock valued at $4,819,000 after purchasing an additional 7,605 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Ikena Oncology by 5.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 66,810 shares of the company’s stock valued at $408,000 after purchasing an additional 3,276 shares during the period. Finally, State Street Corp boosted its position in shares of Ikena Oncology by 18.8% during the first quarter. State Street Corp now owns 404,602 shares of the company’s stock valued at $2,468,000 after purchasing an additional 63,988 shares in the last quarter. 86.01% of the stock is owned by hedge funds and other institutional investors.
Ikena Oncology Company Profile
Ikena Oncology, Inc operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway.
- Five stocks we like better than Ikena Oncology
- Industrial Products Stocks Investing
- Amazon, Target, Walmart in a race for fastest delivery
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Palo Alto Networks: the one security stock to rule them all
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.